Stefania Zambelli

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer, Oleg Lipatov, Seock‐Ah Im et al. · The Lancet Oncology · 2021 · 469 citations

Breast Oncology, Oncology, Clinical Trials +7

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2022 · 365 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +7

Spatial predictors of immunotherapy response in triple-negative breast cancer

Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang et al. · Nature · 2023 · 278 citations · Full text

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli et al. · The Lancet Oncology · 2020 · 251 citations

Breast Oncology, Standard-of-care Chemotherapy, Medicine +7

Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Cancer Research · 2020 · 134 citations

Breast Oncology, Pathologic Complete Response, High Proliferation +18